Relay Therapeutics (RLAY)
(Real Time Quote from BATS)
$3.51 USD
-0.02 (-0.57%)
Updated Aug 6, 2025 03:16 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RLAY 3.51 -0.02(-0.57%)
Will RLAY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RLAY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLAY
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
RLAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Other News for RLAY
Preview: Relay Therapeutics's Earnings
Relay Therapeutics: What's Next For H2 2025?
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights ...
Relay Therapeutics has positive read from Celcuity data, says Barclays
Claire Mazumdar Joins Relay Therapeutics as Director